Aadi Bioscience, Inc. Common Stock

Aadi Bioscience announced it filed a definitive proxy statement and scheduled a special meeting of stockholders for February 28, 2025 to vote on the sale of FYARRO to Kaken Pharmaceuticals for $100 million, the in-licensing of a portfolio of antibody drug conjugates from WuXi Biologics, and a $100 million PIPE financing.

Related tickers: AADI, WXXWY.

Here is how Align Technology (ALGN) and Aadi Bioscience, Inc. (AADI) have performed compared to their sector so far this year.

Related tickers: ALGN, AADI.